8 terminated. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 3 | 1 | Terminated 1 |
Follow Pneumovirus Infections: new trials by email Literature Review of Pneumovirus Infections trials Research Report on Pneumovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 4 | 2025-03-05 | 2026-06-08 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 150 | 2024-10-14 | 2026-06-30 |
| A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Sisunatovir, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Terminated | Pfizer | 16 | 2023-12-08 | 2025-11-10 |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract EDP-938, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Enanta Pharmaceuticals, Inc | 9 | 2021-07-07 | 2024-08-22 |
| Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Janssen Sciences Ireland UC | 3 | 2019-12-26 | 2025-02-04 |
| Anti-RSV Study in Chinese Patients (ASCENT) AK0529, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Shanghai Ark Biopharmaceutical Co., Ltd. | 1 | 2019-03-28 | 2026-06-22 |
| Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection JNJ-53718678, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Janssen Research & Development, LLC | 246 | 2018-11-29 | 2025-02-04 |
| Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients PC786, Placebo, SOC - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Pulmocide Ltd | 5 | 2018-11-05 | 2019-06-12 |
Respiratory Syncytial Virus Infections (8)
Infections (8) · Mononegavirales Infections (8) · Paramyxoviridae Infections (8) · RNA Virus Infections (8) · Virus Diseases (8)
JNJ-53718678 (2) · EDP-938 (1) · PC-786 (1) · sisunatovir (1) · ziresovir (1)
Gilead Sciences (2) · Enanta Pharmaceuticals, Inc (1) · Janssen Research & Development, LLC (1) · Janssen Sciences Ireland UC (1) · Pfizer (1) · Pulmocide Ltd (1) · Shanghai Ark Biopharmaceutical Co., Ltd. (1)
United States (6) · Japan (4) · United Kingdom (4) · Argentina (3) · Belgium (3) · Brazil (3) · China (3) · France (3) · Italy (3) · South Korea (3) · Spain (3) · Taiwan (3) · Bulgaria (2) · Israel (2) · Malaysia (2)
Alison Murray (1)
2016 (1), 2018 (1), 2019 (1), 2023 (1)